• Sunshine Biopharma closed a public offering raising about $6 million in gross proceeds.
• Deal included 10,909,082 common units or pre-funded units priced at $0.55 per unit.
• Each unit carried two Series D warrants with a $0.66 exercise price, exercisable immediately with a five-year term.
• Full cash exercise of the Series D warrants could raise about $14.4 million in additional gross proceeds.
• Net proceeds earmarked for general corporate purposes and working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610091117ACCESSWRNAPR_____1235050) on October 09, 2026, and is solely responsible for the information contained therein.